Telix Pharmaceuticals Limited (NASDAQ:TLX – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $21.00.
Several analysts have issued reports on the company. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Citigroup began coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They set a “buy” rating and a $22.00 target price on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th.
Get Our Latest Stock Analysis on Telix Pharmaceuticals
Hedge Funds Weigh In On Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
TLX stock opened at $10.80 on Monday. The business has a 50 day simple moving average of $10.30 and a 200-day simple moving average of $14.09. Telix Pharmaceuticals has a 1 year low of $8.93 and a 1 year high of $30.36.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals
- Following Congress Stock Trades
- JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?
- Industrial Products Stocks Investing
- Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
- How to Short Nasdaq: An Easy-to-Follow Guide
- As Global Renewables Surpass Coal, This ETF Offers Smart Exposure
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.